Krystal Biotech (KRYS) EBITDA (2016 - 2026)
Krystal Biotech recorded quarterly EBITDA of $53.2 million in Q1 2026, up 3.38% quarter-over-quarter from $51.4 million in Q4 2025, and up 46.43% year-over-year from $36.3 million in Q1 2025.
Krystal Biotech's EBITDA history runs 11 years deep, the most recent figure standing at $53.2 million for Q1 2026.
- In Q1 2026, EBITDA rose 46.43% year-over-year to $53.2 million; the TTM figure through Mar 2026 stood at $223.0 million (up 78.92% YoY), while the FY2025 annual figure was $206.2 million, up 133.39% from the prior year.
- EBITDA came in at $53.2 million for Q1 2026 at Krystal Biotech, up from $51.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $80.6 million in Q3 2023 to a low of -$51.0 million in Q1 2022.
- A 5-year average of $12.9 million and a median of $15.2 million in 2024 frame the typical range for EBITDA.
- Across the five-year window, EBITDA sank 222.47% in 2022 and jumped 726360.0% in 2025, its largest moves.
- Krystal Biotech's EBITDA stood at -$31.3 million in 2022, then soared by 131.02% to $9.7 million in 2023, then surged by 350.75% to $43.8 million in 2024, then increased by 17.5% to $51.4 million in 2025, then increased by 3.38% to $53.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $53.2 million, $51.4 million, and $79.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 53.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.17 Mn |
| Dec 31, 2025 | 51.44 Mn |
| Sep 30, 2025 | 79.31 Mn |
| Jun 30, 2025 | 39.10 Mn |
| Mar 31, 2025 | 36.31 Mn |
| Dec 31, 2024 | 43.78 Mn |
| Sep 30, 2024 | 29.33 Mn |
| Jun 30, 2024 | 15.23 Mn |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | 80.60 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -44.72 Mn |
| Dec 31, 2022 | -31.31 Mn |
| Sep 30, 2022 | -29.78 Mn |
| Jun 30, 2022 | -28.46 Mn |
| Mar 31, 2022 | -51.00 Mn |
| Dec 31, 2021 | -21.96 Mn |
| Sep 30, 2021 | -15.58 Mn |
| Jun 30, 2021 | -16.39 Mn |
| Mar 31, 2021 | -15.82 Mn |
| Dec 31, 2020 | -10.40 Mn |
| Sep 30, 2020 | -9.63 Mn |
| Jun 30, 2020 | -6.82 Mn |
| Mar 31, 2020 | -5.33 Mn |
| Dec 31, 2019 | -5.36 Mn |
| Sep 30, 2019 | -4.28 Mn |
| Jun 30, 2019 | -5.35 Mn |
| Mar 31, 2019 | -4.10 Mn |
| Dec 31, 2018 | -3.71 Mn |
| Sep 30, 2018 | -2.75 Mn |
| Jun 30, 2018 | -2.28 Mn |
| Mar 31, 2018 | -2.15 Mn |
| Dec 31, 2017 | -1.50 Mn |
| Sep 30, 2017 | -5.27 Mn |
| Jun 30, 2017 | -759,000.00 |
| Mar 31, 2017 | -465,000.00 |
| Dec 31, 2016 | -620,000.00 |
| Sep 30, 2016 | -322,000.00 |